Avantor® and cytovance biologics collaborate to accelerate plasmid dna development for biopharma customers

Collaboration will accelerate plasmid optimization and sourcing services for new and existing viral vector and mrna-based vaccine and therapeutic customers radnor, pa. , may 10, 2022 /prnewswire/ -- avantor, inc. (nyse: avtr), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, and cytovance biologics, inc., a biologics contract development and manufacturing organization specializing in the manufacturing of high-quality plasmid dna have entered into an agreement to manufacture research and gmp grade plasmids for biopharma customers.
AVTR Ratings Summary
AVTR Quant Ranking